# How Lipfendra, Inclisiran, and New Guidelines Are Changing Cholesterol Management
Three new developments are reshaping how doctors treat high cholesterol. Two novel medications, Lipfendra and inclisiran, offer alternatives for patients who don't respond well to statins or can't tolerate them. Updated clinical guidelines now reflect these options more prominently in treatment protocols.
Lipfendra combines bempedoic acid with lesinurad, targeting a different metabolic pathway than traditional statins. The drug works by reducing uric acid production while lowering cholesterol, making it useful for patients with both conditions. Clinical trials showed it reduces LDL cholesterol and heart attack risk in people with established heart disease.
Inclisiran takes a different approach. This injectable medication uses RNA interference technology to reduce PCSK9 proteins in the liver, which normally remove LDL cholesterol from the bloodstream. Patients receive injections just twice yearly after an initial loading phase, offering convenience compared to daily pills.
The updated guidelines recognize that one-size-fits-all statin therapy doesn't work for everyone. Some patients experience muscle pain or liver problems. Others have genetic conditions like familial hypercholesterolemia that require more aggressive treatment. These new medications provide doctors with better tools for individualized care.
Cardiologists emphasize that statins remain first-line treatment for most people with high cholesterol or heart disease risk. The new drugs work best when added to existing regimens or when statins alone prove insufficient. Insurance coverage varies, so patients should discuss options with their healthcare provider.
The shift reflects growing recognition that cholesterol management isn't static. As people age or develop new conditions, their treatment needs change. Having multiple effective options allows doctors to adjust therapy based on each patient's response, side effects, and personal health goals.
Patients currently taking statins